Recently, the potential role of vitamins in cancer therapy has attracted considerable research attention. However, the reported findings are inconsistent, with limited information on the biochemical and molecular interactions of different vitamins in various cancer cells. Importantly, the presence of vitamin receptors in tumor cells suggests that vitamins play a significant role in the molecular and biochemical interactions in cancers. Additionally, studies on the efficacy of vitamin supplementation and dosage levels on tumor progression and mortality risk have yielded inconsistent results. Notably, molecular and biochemical investigations have reported the function of vitamins in the proliferation, growth, and invasiveness of tumor cells, as well as in cell cycle arrest and inflammatory signaling. Additionally, different vitamins may regulate the cancer microenvironment by activating various molecular pathways. Vitamins significantly affect immunological function, antioxidant defense, inflammation, and epigenetic control, and can improve treatment outcomes by affecting cell behavior and combating stress and DNA damage. However, further research is necessary to confirm the efficacy of vitamins, establish ideal dosages, and develop effective cancer prevention and treatment plans. Individualized supplementation plans guided by medical knowledge are crucial to achieving optimal results in clinical and preclinical settings. In this review, we critically evaluated the effects of different vitamins on the risk and development of cancer. Additionally, we examined the potential of vitamin supplements to enhance the efficacy of drug therapy and counteract resistance mechanisms that often arise during cancer treatment.
Background: NSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment.Aims: This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach.Methods: Differentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co‐expression was developed with the aim of detecting two modules of gene co‐expression. Following that, the Drug–Gene Interaction Database was used to find possible drugs that target important genes within two gene co‐expression modules linked to non‐small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug–gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs.Results: Unlike previous research on repositioning drugs for NSCLC, which uses a gene co‐expression network, this project is the first to research both gene co‐expression and co‐occurrence networks. And the co‐occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non‐small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug–gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib.Conclusion: Hence, there is a possibility of repurposing these drugs for the treatment of non‐small‐cell lung cancer.
NSCLC is a highly prevalent cancer and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment. This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using systems biology and network analysis approach. Differentially expressed genes of transcriptomics data were identified using the systems biology and network analysis approach. A network of gene co-expression was developed with the aim of detecting two modules of gene co-expression. Subsequently, the Drug-Gene interaction database was employed to pinpoint potential pharmaceutical agents that target crucial genes within two gene co-expression modules associated with non-small cell lung cancer (NSCLC). The construction of a drug-gene interaction network was facilitated with the utilisation of Cytoscape. Finally, the gene set enrichment analysis was done to validate candidate drugs. Unlike previous research on repositioning drugs for NSCLC, which uses a gene co-expression network, this project is the first to research both gene co-expression and co-occurrence networks. And the co-occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. Drugs exhibiting elevated gene regulation and gene affinity within the drug-gene interaction network are deemed noteworthy for the efficacious management of non-small cell lung cancer (NSCLC). According to this discourse, NSCLC genes exert a high degree of regulation over medications such as vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib. Hence, there is a possibility of repurposing these drugs for the treatment of non-small cell lung cancer. Key words: Non-small cell lung cancer (NSCLC), drug repurposing, network analysis, drug-gene interaction, therapeutics
Triple-negative breast cancer (TNBC) is a deadly form of breast cancer that lacks estrogen, progesterone, and HER2 receptors. The development of drugs for TNBC has been challenging due to the lack of specific therapeutic targets. However, recent studies have shown that targeting the ATP active of the PDK-1 and PLK-1 proteins could be potential drug targets for TNBC treatment. New medications for TNBC have considerable adverse effects, highlighting the need for more targeted and effective therapies. In this study, we employed various computational approaches, including molecular docking, molecular dynamics (MD) simulations, pharmacokinetic studies, binding free energy calculations, principal component analysis (PCA), and alanine scanning analysis, to identify bioactive compounds from Daucus carota- extracted natural compounds that can bind to these ATP-binding sites and inhibit the activity of PDK1 and PLK1. Our study revealed that eight compounds showed reasonably good docking scores, binding free energies, and ADMET properties against the PDK1 and PLK1 enzymes. Astragalin and scolimoside showed substantial binding affinity and persistent interactions in the pocket region of the two proteins. Further MD simulation studies for 150 ns also suggested that the compounds were stably bound in the active site with very minor fluctuations. We believe that the identified hits for PDK1 and PLK1 from Daucus carota will be effective against TNBC in performing the biological assays.